Clinical Trial Update: A Study to Explore the Efficacy and Safety of Atezolizumab Plus Tiragolumab and Chemotherapy in 1st Line HER2 Negative Unresectable, Recurrent or Metastatic Gastric Cancer or Adenocarcinoma of Gastroesophageal Junction (GEJ) [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating atezolizumab plus tiragolumab with chemotherapy in first-line HER2-negative unresectable, recurrent, or metastatic gastric cancer or …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• Atezolizumab (atezolizumab)
• Tiragolumab (tiragolumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Stomach Neoplasms, Gastric Cancer | Phase 2 | Status: TERMINATED